Trends in US prices for commonly used drugs assessed by GAO

16 March 2011

According to a new report from the USA’s Government Accounting Office, prescription drug spending in 2009 totaled approximately $250 billion, of which $78 billion - or about 31% - was spent by the federal government.

Prescription drug spending by the federal government, patients, and third-party payers, including employers, is driven by many factors, including the prices paid for drugs. In 2007 the GAO reported on trends in retail prices - known as usual and customary (U&C) prices - for prescription drugs. It found that the average U&C price for the commonly used brand-name prescription drugs reviewed increased about 6% per year from January 2000 through January 2007.

Study requested by Congress

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics